NCT06928779View on ClinicalTrials.gov

Effects of Hepatic Impairment on the Pharmacokinetics of Dazucorilant

PHASE1CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

October 8, 2024

Primary Completion Date

December 9, 2024

Study Completion Date

December 9, 2024

Conditions
Hepatic Impairment
Interventions
DRUG

Dazucorilant

Dazucorilant 300 mg (4 X 75 mg) soft gelatin capsules for oral administration

Trial Locations (2)

33014

Site 1, Miami

92377

Site 2, Rialto

Sponsors
All Listed Sponsors
lead

Corcept Therapeutics

INDUSTRY